Nutraceuticals for Non-alcoholic Fatty Liver Disease

[1]  D. Prati,et al.  Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  R. Carr,et al.  Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity , 2019, Current Obesity Reports.

[3]  N. Chalasani,et al.  Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[4]  M. Marcus,et al.  Psychosocial Concerns Following Bariatric Surgery: Current Status , 2019, Current Obesity Reports.

[5]  M. Croyal,et al.  Spirulina Liquid Extract Protects against Fibrosis Related to Non-Alcoholic Steatohepatitis and Increases Ursodeoxycholic Acid , 2019, Nutrients.

[6]  J. López-Miranda,et al.  Coenzyme Q10: From bench to clinic in aging diseases, a translational review , 2019, Critical reviews in food science and nutrition.

[7]  M. Yamada,et al.  Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients , 2018, Obesity Surgery.

[8]  M. Moosazadeh,et al.  The Effects of Coenzyme Q10 Supplementation on Lipid Profiles Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials. , 2018, Current pharmaceutical design.

[9]  D. D. de Luis,et al.  Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease. , 2018, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[10]  S. Bellentani,et al.  Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence , 2018, Nutrients.

[11]  Rebeca García‐Román,et al.  Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. , 2018, European journal of gastroenterology & hepatology.

[12]  Jiang Cao,et al.  Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2018, Biomedical reports.

[13]  Dave L Dixon,et al.  Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review , 2018, Current Atherosclerosis Reports.

[14]  J. Gunton,et al.  Vitamin D and the Liver—Correlation or Cause? , 2018, Nutrients.

[15]  K. Freitas,et al.  An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease , 2018, Molecules.

[16]  F. Shahidi,et al.  Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. , 2018, Annual review of food science and technology.

[17]  H. Bodenheimer,et al.  Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. , 2018, Clinics in liver disease.

[18]  M. Trauner,et al.  Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2018, Annual review of pathology.

[19]  V. Wong,et al.  The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups , 2018, Journal of gastroenterology and hepatology.

[20]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[21]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[22]  V. Wong.  Current Prevention and Treatment Options for NAFLD. , 2018, Advances in experimental medicine and biology.

[23]  A. Tsung,et al.  The Effects of Physical Exercise on Fatty Liver Disease. , 2018, Gene expression.

[24]  F. Shidfar,et al.  Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial. , 2017, Clinical nutrition.

[25]  Huimao Zhang,et al.  The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease , 2017, Medicine.

[26]  Houkai Li,et al.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy , 2017, Nutrients.

[27]  Manuel Romero-Gómez,et al.  Treatment of NAFLD with diet, physical activity and exercise. , 2017, Journal of hepatology.

[28]  A. Lonardo,et al.  Nonalcoholic fatty liver disease: Evolving paradigms , 2017, World journal of gastroenterology.

[29]  T. Lehtimäki,et al.  Cardiorespiratory Fitness and Risk of Fatty Liver: The Young Finns Study , 2017, Medicine and science in sports and exercise.

[30]  S. Ima-Nirwana,et al.  Vitamin E As a Potential Interventional Treatment for Metabolic Syndrome: Evidence from Animal and Human Studies , 2017, Front. Pharmacol..

[31]  A. Said,et al.  Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. , 2017, Annals of hepatology.

[32]  A. Lonardo,et al.  Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. , 2017, Metabolism: clinical and experimental.

[33]  T. Manohar,et al.  Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis , 2017, Euroasian journal of hepato-gastroenterology.

[34]  Habib-ur-Rehman,et al.  Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients , 2017, Pakistan journal of medical sciences.

[35]  Xuchen Zhang,et al.  Non-alcoholic fatty liver disease: An expanded review , 2017, World journal of hepatology.

[36]  S. Upala,et al.  Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[37]  G. Marchesini,et al.  AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[38]  J. Dufour,et al.  The therapeutic landscape of non‐alcoholic steatohepatitis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[39]  K. Tsuneyama,et al.  Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice. , 2017, Metabolic syndrome and related disorders.

[40]  E. Disse,et al.  EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? , 2017, Diabetologia.

[41]  Y. Panahi,et al.  Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial , 2017, Drug Research.

[42]  C. Thongprayoon,et al.  Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis , 2017, European journal of gastroenterology & hepatology.

[43]  M. del Ben,et al.  The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. , 2017, British journal of clinical pharmacology.

[44]  A. Sahebkar,et al.  Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. , 2016, Nutrition.

[45]  Y. Ni,et al.  Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease , 2016, International journal of molecular sciences.

[46]  Y. Panahi,et al.  Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[47]  O. Chun,et al.  Vitamin C and Heart Health: A Review Based on Findings from Epidemiologic Studies , 2016, International journal of molecular sciences.

[48]  Chunyan Wang,et al.  The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis , 2016, Evidence-based complementary and alternative medicine : eCAM.

[49]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[50]  C. Catalano,et al.  No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial , 2016, BMC Medicine.

[51]  L. Henry,et al.  Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. , 2016, Gastroenterology.

[52]  M. Mohammadshahi,et al.  Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial , 2016, Journal of the American College of Nutrition.

[53]  B. Ji,et al.  Fructose and glucose combined with free fatty acids induce metabolic disorders in HepG2 cell: A new model to study the impacts of high-fructose/sucrose and high-fat diets in vitro. , 2016, Molecular nutrition & food research.

[54]  G. Hatch,et al.  Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway , 2016, PloS one.

[55]  Qifu Li,et al.  Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity , 2016, Scientific Reports.

[56]  P. Kuo,et al.  Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. , 2016, Journal of clinical lipidology.

[57]  F. Piscaglia,et al.  Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study , 2016, Hepatology.

[58]  W. Cai,et al.  Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. , 2016, Archives of Iranian medicine.

[59]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[60]  Shelly C. Lu,et al.  Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis. , 2016, Journal of hepatology.

[61]  A. Feizi,et al.  The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease , 2016, International journal of preventive medicine.

[62]  Hong-wei Zhang,et al.  Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults , 2016, Scientific Reports.

[63]  A. Cicero,et al.  Berberine and Its Role in Chronic Disease. , 2016, Advances in experimental medicine and biology.

[64]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[65]  B. Aggarwal,et al.  Anti-inflammatory Nutraceuticals and Chronic Diseases , 2016, Advances in Experimental Medicine and Biology.

[66]  F. Aucejo,et al.  Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis , 2016, Hepatology International.

[67]  Y. Panahi,et al.  Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. , 2015, Clinical nutrition.

[68]  Nayoung Kim,et al.  Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study , 2015, Clinical and molecular hepatology.

[69]  S. Kaneko,et al.  Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E , 2015, Scientific Reports.

[70]  G. Labbadia,et al.  Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis , 2015, Clinical and Translational Gastroenterology.

[71]  S. Roberts,et al.  High-dose vitamin D supplementation and liver histology in NASH , 2015, Gut.

[72]  A. Hekmatdoost,et al.  The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study , 2015, British Journal of Nutrition.

[73]  A. Sanyal,et al.  Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[74]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[75]  M. Banach,et al.  Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. , 2015, Journal of clinical lipidology.

[76]  M. Gosho,et al.  Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. , 2015, Nutrition.

[77]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[78]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[79]  W. Ling,et al.  A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients With Nonalcoholic Fatty Liver Disease , 2015, Medicine.

[80]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[81]  Zamir Halpern,et al.  Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. , 2015, Translational research : the journal of laboratory and clinical medicine.

[82]  Yu Qin,et al.  Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[83]  G. de Stefano,et al.  Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study , 2015, Drugs in R&D.

[84]  Peter F Surai.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives , 2015, Antioxidants.

[85]  M. Eliades,et al.  Vitamin D: a new player in non-alcoholic fatty liver disease? , 2015, World journal of gastroenterology.

[86]  V. Wong,et al.  Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. , 2015, Journal of hepatology.

[87]  M. Brosnan,et al.  Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism , 2015, Amino Acids.

[88]  M. Rafraf,et al.  Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. , 2014, Journal of dairy science.

[89]  K. Klein,et al.  Resveratrol does not benefit patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  J. Lykkesfeldt,et al.  Does Vitamin C Deficiency Promote Fatty Liver Disease Development? , 2014, Nutrients.

[91]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[92]  G. Wakabayashi,et al.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments , 2014, Front. Endocrinol..

[93]  Y. Panahi,et al.  Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. , 2014, Complementary therapies in medicine.

[94]  J. Panahi,et al.  Data from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver Disease , 2014, Bioinformation.

[95]  B. Neuschwander‐Tetri,et al.  Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[96]  J. Allard,et al.  A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. , 2014, Journal of the Academy of Nutrition and Dietetics.

[97]  N. Sharifi,et al.  Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial , 2014, Endocrine.

[98]  Li Ying,et al.  Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta‐analysis of diagnostic accuracy , 2014, Journal of gastroenterology and hepatology.

[99]  G. Bedogni,et al.  Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis , 2014, Alimentary pharmacology & therapeutics.

[100]  V. Fogliano,et al.  Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. , 2014, Translational research : the journal of laboratory and clinical medicine.

[101]  S. Wild,et al.  Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. , 2014, Journal of hepatology.

[102]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: a practical approach to treatment , 2014, Frontline Gastroenterology.

[103]  M. Papadomanolaki,et al.  The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study , 2014, Annals of gastroenterology.

[104]  Guo-Chong Chen,et al.  Vitamin C Intake, Circulating Vitamin C and Risk of Stroke: A Meta‐Analysis of Prospective Studies , 2013, Journal of the American Heart Association.

[105]  T. Ueno,et al.  Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. , 2013, International journal of molecular medicine.

[106]  Luca Valenti,et al.  Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment , 2013, Current pharmaceutical design.

[107]  George Q. Li,et al.  Herbal medicines for fatty liver diseases. , 2013, The Cochrane database of systematic reviews.

[108]  F. Azizi,et al.  The association of dietary phytochemical index and cardiometabolic risk factors in adults: Tehran Lipid and Glucose Study. , 2013, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[109]  F. Cacciapuoti,et al.  Silymarin in non alcoholic fatty liver disease. , 2013, World journal of hepatology.

[110]  C. Couto,et al.  Dietary patterns in Brazilian patients with non-alcoholic fatty liver disease: a cross-sectional study , 2013, Clinics.

[111]  A. Hofman,et al.  Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. , 2012, Journal of hepatology.

[112]  G. Silecchia,et al.  Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus , 2012, Hepatology.

[113]  R. Ross,et al.  Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. , 2012, The American journal of clinical nutrition.

[114]  F. Shidfar,et al.  A 12-week double-blind randomized clinical trial of vitamin D3 supplementation on body fat mass in healthy overweight and obese women , 2012, Nutrition Journal.

[115]  Z. Halpern,et al.  Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. , 2012, Journal of hepatology.

[116]  I. de Sio,et al.  Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. , 2012, Free radical biology & medicine.

[117]  N. Chavez-Tapia,et al.  High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. , 2012, Annals of hepatology.

[118]  Catriona A. Burdon,et al.  Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.

[119]  R. Loomba,et al.  Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis , 2012, Alimentary pharmacology & therapeutics.

[120]  Yumi Nakamura,et al.  Effects of dietary supplementation with betaine on a nonalcoholic steatohepatitis (NASH) mouse model. , 2012, Journal of nutritional science and vitaminology.

[121]  J. Hardin,et al.  Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington’s disease patients , 2012, Neurological Sciences.

[122]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[123]  J. Crowley,et al.  Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .

[124]  D. D. de Luis,et al.  Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. , 2011, European review for medical and pharmacological sciences.

[125]  S. Morini,et al.  Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes , 2011, BMC medicine.

[126]  A. Franzese,et al.  Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease , 2011, Journal of pediatric gastroenterology and nutrition.

[127]  C. Loguercio,et al.  Silybin and the liver: from basic research to clinical practice. , 2011, World journal of gastroenterology.

[128]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[129]  G. Bedogni,et al.  Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial , 2011, Archives of Disease in Childhood.

[130]  C. Karkos,et al.  Spirulina in Clinical Practice: Evidence-Based Human Applications , 2010, Evidence-based complementary and alternative medicine : eCAM.

[131]  F. Sofi,et al.  Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study , 2010, International journal of food sciences and nutrition.

[132]  R. Capasso,et al.  Milk thistle in liver diseases: past, present, future , 2010, Phytotherapy research : PTR.

[133]  P. R. Vuddanda,et al.  Berberine: a potential phytochemical with multispectrum therapeutic activities , 2010, Expert opinion on investigational drugs.

[134]  A. Hida,et al.  Fatty liver incidence and predictive variables , 2010, Hypertension Research.

[135]  F. Galvano,et al.  l-Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis—A Randomized and Controlled Clinical Trial , 2010, The American Journal of Gastroenterology.

[136]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[137]  Q. Garrett,et al.  Role of carnitine in disease , 2010, Nutrition & metabolism.

[138]  C. Rogenstein,et al.  Dietary and physical activity patterns in children with fatty liver , 2010, European Journal of Clinical Nutrition.

[139]  Morton B. Brown,et al.  Serum 25-Hydroxy Vitamin D and Insulin Resistance, Metabolic Syndrome, and Glucose Intolerance Among Arab Americans , 2010, Diabetes Care.

[140]  M. Trauner,et al.  Fatty liver and lipotoxicity. , 2010, Biochimica et biophysica acta.

[141]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[142]  S. Sanderson,et al.  Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial , 2009, Hepatology.

[143]  F. Steinberg,et al.  Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. , 2009, Metabolism: clinical and experimental.

[144]  F. Marra,et al.  Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. , 2009, Journal of hepatology.

[145]  V. Paradis,et al.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis , 2009, Hepatology.

[146]  G. Salles,et al.  Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[147]  M. Holmqvist,et al.  Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease , 2009, Scandinavian journal of gastroenterology.

[148]  S. Grundy,et al.  Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans , 2008, Journal of Investigative Medicine.

[149]  V. Schrauwen-Hinderling,et al.  Lipid accumulation in non-adipose tissue and lipotoxicity , 2008, Physiology & Behavior.

[150]  S. Piro,et al.  Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[151]  H. R. Cox,et al.  Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. , 2008, The American journal of clinical nutrition.

[152]  S. Horiuchi,et al.  Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis , 2008, European Journal of Clinical Nutrition.

[153]  G. Targher,et al.  Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[154]  P. Puvanachandra,et al.  Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. , 2007, Clinical medicine.

[155]  Christian Gluud,et al.  Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.

[156]  M. Manco,et al.  Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[157]  A. Saraya,et al.  Oxidant Stress and Antioxidant Status Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2006, Journal of clinical gastroenterology.

[158]  A. Lazenby,et al.  The Prevalence of Nonalcoholic Steatohepatitis is Greater in Morbidly Obese Men Compared to Women , 2006, Obesity surgery.

[159]  Zamir Halpern,et al.  Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[160]  I. de Sio,et al.  A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations , 2006, Gut.

[161]  G. Bedogni,et al.  Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study , 2006, Alimentary pharmacology & therapeutics.

[162]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[163]  I. Gülçin.  Antioxidant and antiradical activities of L-carnitine. , 2006, Life sciences.

[164]  T. Murase,et al.  Exercise and green tea extract stimulate fat oxidation and prevent obesity in mice. , 2005, Medicine and science in sports and exercise.

[165]  Y. Arad,et al.  Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. , 2005, Journal of the American College of Cardiology.

[166]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[167]  Jian-Gao Fan,et al.  Obesity, fatty liver and liver cancer. , 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

[168]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[169]  T. Murase,et al.  Green tea extract improves endurance capacity and increases muscle lipid oxidation in mice. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[170]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[171]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[172]  J. Yodoi,et al.  Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[173]  C. Johnston,et al.  Vitamin C deficiency and depletion in the United States: the Third National Health and Nutrition Examination Survey, 1988 to 1994. , 2004, American journal of public health.

[174]  S. Caldwell,et al.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.

[175]  K. Kaita,et al.  Fatty Infiltration of Liver in Hyperlipidemic Patients , 2000, Digestive Diseases and Sciences.

[176]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[177]  G. Musso,et al.  Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.

[178]  L. Rovati,et al.  Efficacy and Safety of Oral Betaine Glucuronate in Non-alcoholic Steatohepatitis , 2000, Arzneimittelforschung.

[179]  H. Tunstall-Pedoe,et al.  Plasma vitamin C and food choice in the third Glasgow MONICA population survey , 2000, Journal of epidemiology and community health.

[180]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[181]  F. Gordon,et al.  Nonalcoholic Steatohepatitis , 1997, Annals of Internal Medicine.

[182]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.